Date Document
11/12/2017 Zelda joins with US Children's Hospital for autism study
08/12/2017 Trading Halt
05/12/2017 Response to ASX Aware Query
29/11/2017 Australian Regulators Approve Zelda Insomnia Clinical Trial
24/11/2017 Results of Meeting
24/11/2017 Annual General Meeting Presentation 2017
24/11/2017 Chairman's Address - Annual General Meeting
22/11/2017 Response to ASX Price and Volume Query
21/11/2017 Trading Halt
16/11/2017 Appendix 3B - Release of Securities from Escrow
01/11/2017 Release from Escrow
31/10/2017 September 2017 Quarterly Report
31/10/2017 Appendix 4C - quarterly
26/10/2017 Notice of Annual General Meeting
18/09/2017 Successful Results in Autism Observation Trial
18/09/2017 Update on Closing Date of CannPal Priority Offer
13/09/2017 Update on Research Programme in Chile
31/08/2017 Appendix 4G
31/08/2017 Appendix 4E & Financial Statements
31/08/2017 CannPal Priority Share Offer Clarification Announcement
29/08/2017 Priority Share Offer for CannPal IPO Shares
25/08/2017 Company Presentation on 2017 Half Year Activities
31/07/2017 Expansion of Breast Cancer Research Collaboration
28/07/2017 June 2017 Quarterly Report
28/07/2017 Appendix 4C - quarterly
26/07/2017 ENT:Acquisition of prospective Au& Cu/Zn Murchison Tenements
30/06/2017 Updated Securities Trading and Corporate Governance Policies
15/06/2017 Zelda Enters into Strategic Agreement with Knop Laboratories
02/06/2017 Positive Results From Pre-Clinical Breast Cancer Studies
28/04/2017 March 2017 Quarterly Report
28/04/2017 Appendix 4C - quarterly
21/04/2017 Appendix 3B - Release of Securities from Escrow
19/04/2017 Clinical Research Programme to Expand to Include Autism
06/04/2017 Change in substantial holding x 3
05/04/2017 Appendix 3B
04/04/2017 Release from Escrow
03/04/2017 Cleansing Prospectus
30/03/2017 Zelda Successfully Completes Capital Raising
28/03/2017 Trading Halt
27/03/2017 Zelda Enters Strategic Partnership with CannPal
23/03/2017 Clinical Trials to Commence in Chile
21/03/2017 New Licence Agreement
14/03/2017 Closure of Unmarketable Parcel Share Sale Facility
27/02/2017 Appendix 4D & FY17 Interim Financial Report
21/02/2017 Zelda Therapeutics to present activities update
08/02/2017 Investor Presentation
06/02/2017 Issue of Options under ESOP & Appendix 3B
31/01/2017 Quarterly Report and Appendix 4C
19/01/2017 Unmarketable Parcel Share Sale Facility
11/01/2017 Appendix 3B
11/01/2017 Release from escrow
11/01/2017 Details of Company Address
09/01/2017 Shareholder Update